Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: results from Early Prostate Cancer Trial 24 at a median 7 years' follow-up

Abstract

Trial 24, one of three ongoing trials in the Early Prostate Cancer programme, is evaluating the efficacy and tolerability of bicalutamide (Casodex) 150 mg following standard care (radiotherapy, radical prostatectomy or watchful waiting) in patients with early, non-metastatic prostate cancer. At 7 years' median follow-up, addition of bicalutamide significantly improved objective progression-free survival (PFS) for patients with locally advanced disease, reducing the risk of progression by 34% versus standard care alone (hazard ratio 0.66; 95% confidence interval 0.55, 0.79; P<0.001). In localized disease, a significant difference in objective PFS was not found. There was no significant difference in overall survival.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Smith Jr JA, Soloway MS, Young MJ . Complications of advanced prostate cancer. Urology 1999; 54 (Suppl 6A): 8–14.

    Article  Google Scholar 

  2. Pitceathly C, Maguire P . The psychological impact of cancer on patients' partners and other key relatives: a review. Eur J Cancer 2003; 39: 1517–1524.

    Article  CAS  Google Scholar 

  3. Penson DF, Moul JW, Evans CP, Doyle JJ, Gandhi S, Lameratp L . The economic burden of metastatic and prostate specific antigen progression in patients with prostate cancer: findings from a retrospective analysis of health plan data. J Urol 2004; 171: 2250–2254.

    Article  Google Scholar 

  4. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff R-O et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002; 360: 103–108.

    Article  CAS  Google Scholar 

  5. Pilepich MV, Winter K, Lawton CA, Krish RE, Wolkov HB, Movsas B et al. Androgen suppression adjuvant to definitive radiotherapy in carcinomas of the prostate – long term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005; 61: 1285–1290.

    Article  CAS  Google Scholar 

  6. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D . Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999; 341: 1781–1788.

    Article  CAS  Google Scholar 

  7. Messing E, Manola J, Sarosdy M, Wilding G, Crawford ED . Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node positive prostate cancer: results at 10 years of EST 3886. J Urol 2003; 169: 396, 1480.

    Google Scholar 

  8. Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, Van Poppel H, Tammela TL et al. Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J Urol 2000; 164: 1579–1582.

    Article  CAS  Google Scholar 

  9. Sieber PR, Keiller DL, Kahnoski RJ, Gallo J, McFadden S . Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. J Urol 2004; 171: 2272–2276.

    Article  CAS  Google Scholar 

  10. Stephenson RA . Prostate cancer trends in the era of prostate-specific antigen. An update of incidence, mortality, and clinical factors from the SEER database. Urol Clin North Am 2002; 29: 173–181.

    Article  Google Scholar 

  11. Anderson J . The role of antiandrogen monotherapy in the treatment of prostate cancer. BJU Int 2003; 91: 455–461.

    Article  CAS  Google Scholar 

  12. McLeod DG, Iversen P, See WA, Morris T, Armstrong J, Wirth MP, on behalf of the ‘Casodex’ Early Prostate Cancer Trialists' Group. Bicalutamide 150 mg plus standard care versus standard care alone for early prostate cancer. BJU Int 2006; 97: 247–254.

    Article  CAS  Google Scholar 

  13. Aus G, Abbou CC, Bolla M, Heidenreich A, Van Poppel H, Schmid H-P et al. European Association of Urology Guidelines on Prostate Cancer. Available at: http://www.uroweb.nl/files/uploaded_files/2005Prostate%20Cancer.pdf. Accessed December 19, 2005.

  14. McLeod DG . Tolerability of nonsteroidal antiandrogens in the treatment of advanced prostate cancer. Oncologist 1997; 2: 18–27.

    CAS  PubMed  Google Scholar 

  15. Wirth M, Tyrrell C, Wallace M, Delaere KP, Sánchez-Chapado M, Ramon J et al. Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression. Urology 2001; 58: 146–151.

    Article  CAS  Google Scholar 

  16. Wirth M, Tyrrell C, Delaere K, Sanchez-Chapado M, Ramon J, Wallace DM et al. Bicalutamide (‘Casodex’) 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double-blind phase III study (median follow-up 5.1 y) in the early prostate cancer programme. Prostate Cancer Prostatic Dis 2005; 8: 194–200.

    Article  CAS  Google Scholar 

  17. See WA, Wirth MP, McLeod DG, Iversen P, Klimberg I, Gleason D, et al., on behalf of the Casodex Early Prostate Cancer Trialist Group. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. J Urol 2002; 168: 429–435.

    Article  CAS  Google Scholar 

  18. Wirth MP, See WA, McLeod D, Iversen P, Morris T, Carroll K, Casodex Early Prostate Cancer Trialists' Group. Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years. J Urol 2004; 172: 1865–1870.

    Article  CAS  Google Scholar 

  19. See WA, McLeod D, Iversen P, Wirth M . The bicalutamide Early Prostate Cancer program: demography. Urol Oncol 2001; 6: 43–47.

    Article  Google Scholar 

  20. Iversen P, Johansson J-E, Lodding P, Kylmälä T, Lundmo P, Klarskov P, et al., on behalf of the Scandinavian Prostate Cancer Group. Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer: updated results from the Scandinavian Prostate Cancer Group (SPCG) Study 6 at 7.1-years' median follow-up. Scand J Urol Nephrol 2006 (in press).

Download references

Author information

Authors and Affiliations

Authors

Consortia

Corresponding author

Correspondence to M Wirth.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wirth, M., Tyrrell, C., Delaere, K. et al. Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: results from Early Prostate Cancer Trial 24 at a median 7 years' follow-up. Prostate Cancer Prostatic Dis 10, 87–93 (2007). https://doi.org/10.1038/sj.pcan.4500916

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.pcan.4500916

Keywords

This article is cited by

Search

Quick links